Skip to main content

RxSight, Inc. Educational and Product Announcements for AAO 2023

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco. These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229). At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens™ (LAL®) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision. For the full program of events taking place at AAO 2023, click here.

One of these presentations (by Steven Slade, MD, of Houston-based Slade & Baker Vision on November 4 at 10:30 a.m.) will report clinical results using the LAL+, a new addition to the LAL family that will become available in the first quarter of 2024. The LAL+ has a built-in optical feature that is designed to further extend the depth of focus before light treatments, while preserving the high-quality vision of the LAL already familiar to customers and patients.

RxSight’s reconfigured Light Delivery Device (LDD™) will also be on display during AAO. While providing the same functionality and outcomes as the standard LDD, this compact model has a smaller footprint to address global practice space constraints.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
ir@rxsight.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.48
+3.44 (1.61%)
AAPL  262.24
+9.95 (3.94%)
AMD  240.56
+7.48 (3.21%)
BAC  52.04
+0.76 (1.48%)
GOOG  257.02
+3.23 (1.27%)
META  732.17
+15.26 (2.13%)
MSFT  516.79
+3.21 (0.63%)
NVDA  182.64
-0.58 (-0.32%)
ORCL  277.18
-14.13 (-4.85%)
TSLA  447.43
+8.12 (1.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.